Please enable JavaScript to continue using this application.

Compare $BBOT vs $LXEO | Chartloom

Compare

$BBOT vs $LXEO

BridgeBio Oncology Therapeutics Inc · Lexeo Therapeutics Inc

BBOT

BridgeBio Oncology Therapeutics Inc

LXEO

Lexeo Therapeutics Inc

Compare $BBOT vs $LXEO

Comparing BridgeBio Oncology Therapeutics Inc and Lexeo Therapeutics Inc

BBOTBridgeBio Oncology Therapeutics Inc

LXEOLexeo Therapeutics Inc

BBOTBridgeBio Oncology Therapeutics Inc

Market cap

$265M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-73.1%

52W performance

-72.5%

FCF yield

-73.1%

LXEOLexeo Therapeutics Inc

Market cap

$254M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-66.4%

52W performance

-59.8%

FCF yield

-35.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

BBOT

LXEO

Detailed metrics comparison

BBOT

BridgeBio Oncology Therapeutics Inc

LXEO

Lexeo Therapeutics Inc

Market Cap

BBOT$265M

LXEO$254M

Enterprise Value

BBOT$211M

LXEO$161M

Price

BBOT$3.31

LXEO$3.23

P/E Ratio

BBOTN/A

LXEON/A

P/S Ratio

BBOT0.00x

LXEO535.16x

EV/Sales

BBOT0.00x

LXEO0.00x

EV/EBITDA

BBOT0.00x

LXEO0.00x

P/B Ratio

BBOT0.97x

LXEO1.23x

P/FCF Ratio

BBOTN/A

LXEON/A

EV/FCF

BBOT-1.09x

LXEO-1.82x

PEG Ratio

BBOTN/A

LXEON/A

Forward P/E (NTM)

BBOTN/A

LXEON/A

Forward P/S (NTM)

BBOTN/A

LXEON/A

Revenue (TTM)

BBOT$0

LXEO$0

Revenue Growth (YoY)

BBOTN/A

LXEON/A

Forward Rev Growth

BBOT540.3%

LXEO466.0%

Gross Margin (TTM)

BBOT0.0%

LXEO0.0%

Operating Margin (TTM)

BBOT0.0%

LXEO0.0%

EBITDA Margin (TTM)

BBOT0.0%

LXEO0.0%

Net Margin (TTM)

BBOT0.0%

LXEO0.0%

FCF Margin (TTM)

BBOTN/A

LXEON/A

Net Income (TTM)

BBOT$-182M

LXEO$-87M

FCF (TTM)

BBOT$-194M

LXEO$-89M

EPS (TTM)

BBOT-$2.27

LXEO-$1.02

ROE (TTM)

BBOT-4690.0%

LXEO-4185.0%

ROA (TTM)

BBOT-4217.0%

LXEO-3803.0%

ROIC (TTM)

BBOT-4690.0%

LXEO-4169.0%

Cash

BBOT$54M

LXEO$93M

Debt

BBOT$0

LXEO$584K

Net Cash/Debt

BBOT$54M

LXEO$92M

Current Ratio (TTM)

BBOT4.69x

LXEO13.89x

Quick Ratio (TTM)

BBOT4.38x

LXEO13.49x

Debt/Equity (TTM)

BBOT0.00x

LXEO0.00x

Debt/Assets (TTM)

BBOT0.0%

LXEO0.0%

Interest Coverage (TTM)

BBOTN/A

LXEON/A

Net Debt/EBITDA (TTM)

BBOT0.00x

LXEO0.00x

Beta

BBOT0.67

LXEO1.62

52W Performance

BBOT-72.5%

LXEO-59.8%

YTD Performance

BBOT-73.1%

LXEO-66.4%

% from 52W High

BBOT-77.7%

LXEO-70.6%

% from 52W Low

BBOT1.2%

LXEO8.4%

Asset Turnover (TTM)

BBOT0.00x

LXEO0.00x

FCF Yield (TTM)

BBOT-73.1%

LXEO-35.0%

Earnings Yield (TTM)

BBOT-68.7%

LXEO-34.4%

Dividend Yield (TTM)

BBOTN/A

LXEON/A

Rule of 40

BBOT0.0

LXEO0.0

EV/GP/RG

BBOTN/A

LXEON/A

Ticker research

View BBOT research View LXEO research

Metric	BBOT BridgeBio Oncology Therapeutics Inc	LXEO Lexeo Therapeutics Inc
Market & Valuation
Market Cap	$265M	$254M
Enterprise Value	$211M	$161M
Price	$3.31	$3.23
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	535.16x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.97x	1.23x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.09x	-1.82x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	540.3%	466.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-182M	$-87M
FCF (TTM)	$-194M	$-89M
EPS (TTM)	-$2.27	-$1.02
ROE (TTM)	-4690.0%	-4185.0%
ROA (TTM)	-4217.0%	-3803.0%
ROIC (TTM)	-4690.0%	-4169.0%
Financial Health
Cash	$54M	$93M
Debt	$0	$584K
Net Cash/Debt	$54M	$92M
Current Ratio (TTM)	4.69x	13.89x
Quick Ratio (TTM)	4.38x	13.49x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.67	1.62
52W Performance	-72.5%	-59.8%
YTD Performance	-73.1%	-66.4%
% from 52W High	-77.7%	-70.6%
% from 52W Low	1.2%	8.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-73.1%	-35.0%
Earnings Yield (TTM)	-68.7%	-34.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View BBOT research	View LXEO research

Valuation

P/S Ratio

BBOT

0.00x

LXEO

535.16x

EV/FCF

LXEO

-1.82x

BBOT

-1.09x

Growth & revenue

Forward Revenue Growth

BBOT

540.3%

LXEO

466.0%

Profitability & performance

Gross Margin

BBOT

0.0%

LXEO

0.0%

ROE

LXEO

-4185.0%

BBOT

-4690.0%

FCF Yield %

LXEO

-35.0%

BBOT

-73.1%

52-Week Performance

LXEO

-59.8%

BBOT

-72.5%

Detailed metrics comparison

BBOT

BridgeBio Oncology Therapeutics Inc

LXEO

Lexeo Therapeutics Inc

Market Cap

BBOT$265M

LXEO$254M

Enterprise Value

BBOT$211M

LXEO$161M

Price

BBOT$3.31

LXEO$3.23

P/E Ratio

BBOTN/A

LXEON/A

P/S Ratio

BBOT0.00x

LXEO535.16x

EV/Sales

BBOT0.00x

LXEO0.00x

EV/EBITDA

BBOT0.00x

LXEO0.00x

P/B Ratio

BBOT0.97x

LXEO1.23x

P/FCF Ratio

BBOTN/A

LXEON/A

EV/FCF

BBOT-1.09x

LXEO-1.82x

PEG Ratio

BBOTN/A

LXEON/A

Forward P/E (NTM)

BBOTN/A

LXEON/A

Forward P/S (NTM)

BBOTN/A

LXEON/A

Revenue (TTM)

BBOT$0

LXEO$0

Revenue Growth (YoY)

BBOTN/A

LXEON/A

Forward Rev Growth

BBOT540.3%

LXEO466.0%

Gross Margin (TTM)

BBOT0.0%

LXEO0.0%

Operating Margin (TTM)

BBOT0.0%

LXEO0.0%

EBITDA Margin (TTM)

BBOT0.0%

LXEO0.0%

Net Margin (TTM)

BBOT0.0%

LXEO0.0%

FCF Margin (TTM)

BBOTN/A

LXEON/A

Net Income (TTM)

BBOT$-182M

LXEO$-87M

FCF (TTM)

BBOT$-194M

LXEO$-89M

EPS (TTM)

BBOT-$2.27

LXEO-$1.02

ROE (TTM)

BBOT-4690.0%

LXEO-4185.0%

ROA (TTM)

BBOT-4217.0%

LXEO-3803.0%

ROIC (TTM)

BBOT-4690.0%

LXEO-4169.0%

Cash

BBOT$54M

LXEO$93M

Debt

BBOT$0

LXEO$584K

Net Cash/Debt

BBOT$54M

LXEO$92M

Current Ratio (TTM)

BBOT4.69x

LXEO13.89x

Quick Ratio (TTM)

BBOT4.38x

LXEO13.49x

Debt/Equity (TTM)

BBOT0.00x

LXEO0.00x

Debt/Assets (TTM)

BBOT0.0%

LXEO0.0%

Interest Coverage (TTM)

BBOTN/A

LXEON/A

Net Debt/EBITDA (TTM)

BBOT0.00x

LXEO0.00x

Beta

BBOT0.67

LXEO1.62

52W Performance

BBOT-72.5%

LXEO-59.8%

YTD Performance

BBOT-73.1%

LXEO-66.4%

% from 52W High

BBOT-77.7%

LXEO-70.6%

% from 52W Low

BBOT1.2%

LXEO8.4%

Asset Turnover (TTM)

BBOT0.00x

LXEO0.00x

FCF Yield (TTM)

BBOT-73.1%

LXEO-35.0%

Earnings Yield (TTM)

BBOT-68.7%

LXEO-34.4%

Dividend Yield (TTM)

BBOTN/A

LXEON/A

Rule of 40

BBOT0.0

LXEO0.0

EV/GP/RG

BBOTN/A

LXEON/A

Ticker research

View BBOT research View LXEO research

Metric	BBOT BridgeBio Oncology Therapeutics Inc	LXEO Lexeo Therapeutics Inc
Market & Valuation
Market Cap	$265M	$254M
Enterprise Value	$211M	$161M
Price	$3.31	$3.23
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	535.16x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.97x	1.23x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.09x	-1.82x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	540.3%	466.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-182M	$-87M
FCF (TTM)	$-194M	$-89M
EPS (TTM)	-$2.27	-$1.02
ROE (TTM)	-4690.0%	-4185.0%
ROA (TTM)	-4217.0%	-3803.0%
ROIC (TTM)	-4690.0%	-4169.0%
Financial Health
Cash	$54M	$93M
Debt	$0	$584K
Net Cash/Debt	$54M	$92M
Current Ratio (TTM)	4.69x	13.89x
Quick Ratio (TTM)	4.38x	13.49x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.67	1.62
52W Performance	-72.5%	-59.8%
YTD Performance	-73.1%	-66.4%
% from 52W High	-77.7%	-70.6%
% from 52W Low	1.2%	8.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-73.1%	-35.0%
Earnings Yield (TTM)	-68.7%	-34.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View BBOT research	View LXEO research